Amyotrophic lateral sclerosis progression: Iran-ALS clinical registry, a multicentre study

Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(7-8):506-11. doi: 10.3109/21678421.2015.1074698. Epub 2015 Oct 5.


This study was designed to evaluate ALS progression among different subgroups of Iranian patients. Three hundred and fifty-eight patients from centres around the country were registered and their progression rate was evaluated using several scores including Manual Muscle Test scoring (MMT) and the revised ALS Functional Rating Scale (ALSFRS-R). Progression rate was analysed separately in subgroups regarding gender, onset site, stage of disease and riluzole consumption. A significant difference in MMT deterioration rate (p = 0.01) was noted between those who used riluzole and those who did not. No significant difference was observed in progression rates between male/female and bulbar-onset/limb-onset groups using riluzole. In conclusion, riluzole has a significant effect on muscle force deterioration rate but not functional scale. Progression rate was not influenced by site of onset or gender.

Keywords: Amyotrophic lateral sclerosis; Manual Muscle Test scoring; progression rate; revised ALS Functional Rating Scale.

Publication types

  • Multicenter Study
  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Amyotrophic Lateral Sclerosis / complications
  • Amyotrophic Lateral Sclerosis / drug therapy
  • Amyotrophic Lateral Sclerosis / physiopathology*
  • Bulbar Palsy, Progressive / etiology
  • Bulbar Palsy, Progressive / physiopathology*
  • Disease Progression
  • Extremities / physiopathology*
  • Female
  • Humans
  • Iran
  • Male
  • Middle Aged
  • Muscle Weakness / etiology
  • Muscle Weakness / physiopathology*
  • Neuroprotective Agents / therapeutic use
  • Prospective Studies
  • Registries*
  • Riluzole / therapeutic use


  • Neuroprotective Agents
  • Riluzole